目的:探讨稳定型心绞痛(SAP)患者血清高迁移率族蛋白1(HMGB1)水平与冠脉粥样硬化斑块稳定性的关系.方法:本研究共纳入266 例SAP 患者.根据患者是否存在不稳定斑块将所有患者分为稳定斑块组(n=121)及不稳定斑块组(n=145),采用酶联免疫吸附(ELISA)法测患者的血清HMGB1 水平.结果:不稳定斑块组血清HMGB1水平[6.17(2.83~11.62)ng/ml]较稳定斑块组[4.23(1.73～7.50)ng/ml]明显升高(P<0.01),多元Logistic 回归分析显示高血清HMGB1 水平与SAP 患者存在不稳定斑块呈独立正相关(OR=2.336,95%CI=1.207～3.988,P<0.05).结论:血清HMGB1 是SAP 患者存在不稳定斑块的独立危险因子,血清HMGB1 有望成为预测SAP 患者冠脉粥样硬化斑块稳定程度的生物学标志物.%Objective: To determine the relationship between serum high-mobility group box 1 (HMGB1) levels and coronary plaque vulnerability in patients with stable angina pectoris (SAP). Methods: A total of 266 SAP patients were enrolled in the present study. All the patients were classified as stable plaques group (n= 121) or vulnerable plaques group (n=145) based on coronary plaque morphology. Serum HMGB1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Results: Serum HMGB1 levels were significantly higher in patients with vulnerable plaques [6.17(2.83-11.62)ng/ml] than those in patients with stable plaques [4.23 (1.73-7.50)ng/ml] (P<0.01). Multivariate Logistic regression showed that serum HMGB1 levels was independently and positively associated with the presence of vulnerable plaques (OR =2.336, 95% CI= 1.207-3.988, P<0.05) in SAP patients. Conclusion: Serum HMGB1 is the independent risk factor for vulnerable plaques in SAP patients. These results indicate that serum HMGB1 might be a potential biomarker for predicting coronary plaque vulnerability in SAP patients.
展开▼
